DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
GS-4997 is an investigational drug.
There have been 9 clinical trials for GS-4997. The most recent clinical trial was a Phase 2 trial, which was initiated on February 13th 2017.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Hepatitis, Alcoholic. The leading clinical trial sponsors are Gilead Sciences, HepQuant, LLC, and [disabled in preview].
There are twenty-five US patents protecting this investigational drug and three hundred and eighty-one international patents.
Recent Clinical Trials for GS-4997
|Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis||Gilead Sciences||Phase 3|
|Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)||Gilead Sciences||Phase 3|
|GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)||Gilead Sciences||Phase 2|
Top disease conditions for GS-4997
Top clinical trial sponsors for GS-4997
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GS-4997||Get Started Free||Fused heterocyclic compounds as CaM kinase inhibitors||Gilead Sciences, Inc. (Foster City, CA)||Get Started Free|
|GS-4997||Get Started Free||ASK1 inhibitor compounds and uses thereof||SEAL ROCK THERAPEUTICS, INC. (Seattle, WA)||Get Started Free|
|GS-4997||Get Started Free||Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof||Gilead Apollo, LLC (Foster City, CA)||Get Started Free|
|GS-4997||Get Started Free||Methods of treating liver disease||Gilead Sciences, Inc. (Foster City, CA)||Get Started Free|
|GS-4997||Get Started Free||Cyclobutyl-imidazolidinone compounds||ELI LILLY AND COMPANY (Indianapolis, IN)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|GS-4997||Argentina||AR110252||2036-11-30||Get Started Free|
|GS-4997||European Patent Office||EP3548495||2036-11-30||Get Started Free|
|GS-4997||Taiwan||TW201831487||2036-11-30||Get Started Free|
|GS-4997||Taiwan||TWI651325||2036-11-30||Get Started Free|
|GS-4997||World Intellectual Property Organization (WIPO)||WO2018102384||2036-11-30||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|